<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02384876</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL14_0248</org_study_id>
    <secondary_id>2014-004190-16</secondary_id>
    <nct_id>NCT02384876</nct_id>
  </id_info>
  <brief_title>Determination of the Optimal Dose of Ephedrine in Intraoperative Arterial Hypotension of Newborns and Infants up to 6 Months of Age.</brief_title>
  <acronym>EPHEDRINE</acronym>
  <official_title>Determination of the Optimal Dose of Ephedrine in Intraoperative Arterial Hypotension of Newborns and Infants up to 6 Months of Age. A Randomized, Controlled, Open-label, Dose Escalation Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of arterial hypotension under general anesthesia using sevoflurane is&#xD;
      particularly high in newborns and infants up to 6 months of age. A decrease of 20% of the&#xD;
      initial mean blood pressure (mBP) is the definition of significant arterial hypotension in&#xD;
      adults and children. In adults, intraoperative arterial hypotension is associated with an&#xD;
      increase of intraoperative mortality and a certain neurological morbidity. In infants under 6&#xD;
      months of age, neurological disorders have been reported following general anesthesia.&#xD;
      Neurotoxicity of hypnotics is often incriminated as should be the episodes of arterial&#xD;
      hypotension.&#xD;
&#xD;
      Current management of hypotension uses vascular filling with crystalloids and vasopressive&#xD;
      amines in second intention. Dopamine is the most frequently used amine. Ephedrine can also be&#xD;
      used. Ephedrine is particularly interesting because of its action on both α and β receptors&#xD;
      and its mode of administration: one dose and peripheral access.&#xD;
&#xD;
      Only one study is available in children from birth to adulthood; it demonstrates a lower&#xD;
      hemodynamic response in infants than in adults, when administered a low dose of Ephedrine&#xD;
      (0.1 to 0.2 mg/kg). A recent retrospective cohort suggests an under efficacy of low doses and&#xD;
      the use of higher doses than those recommended.&#xD;
&#xD;
      The primary objective is to determine the optimal dose of ephedrine (dose of ephedrine&#xD;
      associated with a difference of proportion of newborns/infants in therapeutic success of 55%)&#xD;
      compare to the reference dose of 0.1mg/kg as a first line treatment of intraoperative&#xD;
      arterial hypotension.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Return to a mBP superior to 38mmHg post Ephedrine administration.&#xD;
&#xD;
        -  To assess occurrence of hypoxemic events during anesthesia.&#xD;
&#xD;
        -  To assess tolerance of ephedrine. One hundred and twenty newborn and infants up to 6&#xD;
           months of age will be recruited in 3 sites of the Rhone Alpes Auvergne area over 24&#xD;
           months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">September 5, 2020</completion_date>
  <primary_completion_date type="Actual">September 5, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Therapeutic success is defined as a mBP superior to 55% of the basal mBP (prior to anesthesia) within 10 minutes post Ephedrine administration</measure>
    <time_frame>Continuous monitoring within 10 minutes post-administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Return to a mBP superior to 38mmHg within 10 minutes post Ephedrine administration</measure>
    <time_frame>Continuous monitoring within 10 minutes post-administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations of O2 saturation in cerebral tissue (number of desaturations, evolution under treatment) using a Near Infrared Spectroscopy (NIRS) technology</measure>
    <time_frame>Continuous monitoring within 10 minutes post-administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of Ephedrine: occurrence of serious adverse events</measure>
    <time_frame>During 3 days post-administration</time_frame>
    <description>Clinical examination focusing specifically on heart rate and hypertension</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Intraoperative Arterial Hypotension</condition>
  <condition>Infant, Newborn</condition>
  <arm_group>
    <arm_group_label>Ephedrine, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation: 6 successive cohorts with a maximal increasing dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ephedrine, dose : 0.1 mg/kG, reference dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reference dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG</intervention_name>
    <arm_group_label>Ephedrine, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.1 mg/kG.</intervention_name>
    <arm_group_label>Ephedrine, dose : 0.1 mg/kG, reference dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newborns or infants &lt; 6 months of age,&#xD;
&#xD;
          -  boys and girls,&#xD;
&#xD;
          -  premature or not,&#xD;
&#xD;
          -  requiring general anesthesia induced by sevoflurane&#xD;
&#xD;
          -  who presents during anesthesia a decrease of blood pressure superior to 20% of the&#xD;
             basal mBP (measured prior to surgery) despite of vascular filling with sodium chloride&#xD;
             0.9% (10mL/kg during 10 min).&#xD;
&#xD;
          -  Written, informed consent obtained from the 2 parents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to Ephedrine.&#xD;
&#xD;
          -  Emergency surgery.&#xD;
&#xD;
          -  Patient having previously received other vasopressive amines.&#xD;
&#xD;
          -  Use of other indirect sympathomimetic drug such as phenylpropanolamine, phenylephrine,&#xD;
             pseudoephedrine and methylphenidate.&#xD;
&#xD;
          -  Premedication with clonidine&#xD;
&#xD;
          -  Congenital heart disease&#xD;
&#xD;
          -  IV-induced anesthesia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathilde de Queiroz Siqueira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'anesthésie pédiatrique et obstétricale, Hôpital Femme Mère Enfant, 59 boulevard Pinel - 69 677 BRON Cedex</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital d'Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 27, 2015</study_first_submitted>
  <study_first_submitted_qc>March 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2015</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>intraoperative arterial hypotension</keyword>
  <keyword>ephedrine</keyword>
  <keyword>general anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ephedrine</mesh_term>
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

